Original Articles
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
Steven T. Bird, Abraham G. Hartzema, James M. Brophy, Mahyar Etminan and Joseph A.C. Delaney
CMAJ December 03, 2012 cmaj.120677; DOI: https://doi.org/10.1503/cmaj.120677
Steven T. Bird
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, FL; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC.
Abraham G. Hartzema
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, FL; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC.
James M. Brophy
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, FL; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC.
Mahyar Etminan
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, FL; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC.
Joseph A.C. Delaney
Department of Health and Human Services (Bird), Food and Drug Administration, Center for Drug Evaluation and Research, Office of Management and Academic Collaboration Program; Department of Pharmaceutical Outcome and Policy (Bird, Delaney, Hartzema), University of Florida College of Pharmacy, Gainesville, FL; Department of Medicine and Epidemiology (Brophy), McGill University, Montréal, Que.; Pharmaceutical Outcomes Programme (Etminan), School of Medicine, University of British Columbia, Vancouver, BC.